June 18, 2013 8:38 AM | 1 min read
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
In a report published Tuesday, Bank of America analyst Derik de Bruin downgraded the rating on
Genomic Health (NASDAQ: GHDX) from Buy to Neutral, and lowered the price target from $43.00 to $36.00.In the report, Bank of America noted, “We are impressed by Genomic Health's scientific and commercial expertise as well as its execution to expand its tests' indications, launching new products, and broadening its geographic footprint. However, industry dynamics are also becoming increasingly more difficult due to competition, reimbursement, and regulatory pressures. As a result, we think that share appreciation may be limited over the next 12 months.”Genomic Health closed on Monday at $32.97.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.